AVI Inks Antisense Research Deal with Walter Reed Army Institute of Research

AVI BioPharma said this week that it has signed a deal to conduct collaborative research on the effect of its antisense agents against dengue and other flavivirus infections with the Walter Reed Army Institute of Research.

The effort, said AVI, is part of a cooperative research and development agreement established with WRAIR as part of AVI’s ongoing efforts in biodefense with the Office of the Secretary of Defense.